{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:53:34Z","timestamp":1790178814894,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["14\/155"],"award-info":[{"award-number":["14\/155"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["17\/402"],"award-info":[{"award-number":["17\/402"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["20\/144"],"award-info":[{"award-number":["20\/144"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Genomics Aotearoa"},{"DOI":"10.13039\/501100001516","name":"New Zealand Heart Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001516","id-type":"DOI","asserted-by":"crossref"}]},{"name":"E & W White Parsons Charitable Trust"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Cohort studies have demonstrated associations between calcific aortic valve disease (CAVD) and Lp(a). As Lp(a) is almost entirely genetically determined, in this study, we aim to determine whether Lp(a), when predicted from genetic data, is associated with CAVD and major adverse cardiovascular events (MACEs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Patients undergoing coronary angiography between January 2012 and May 2013 were invited to participate in the study. Of 752 analysable participants, 446 had their Lp(a) measured and 703 had a calculable LPA genetic risk score (GRS). The primary outcomes were the presence of CAVD at baseline and MACE over a 7-year follow-up. The GRS explained 45% of variation in Lp(a). After adjustment for cardiac risk factors and coronary artery disease (CAD), the odds of CAVD increased with increasing Lp(a) [odds ratio (OR) 1.039 per 10-unit increase, 95% confidence interval (CI) 1.022\u20131.057, P &amp;lt; 0.001] and GRS (OR 1.054 per 10-unit increase, 95% CI 1.024\u20131.086; P &amp;lt; 0.001). Lipoprotein(a) and the GRS as continuous variables were not associated with subsequent MACEs. A dichotomized GRS (&amp;gt;54) was associated with MACE, but this relationship became non-significant when CAD classification was added into the model (OR 1.333, 95% CI 0.927\u20131.912; P = 0.12).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>An LPA GRS can explain 45% of variation in Lp(a) levels, and both Lp(a) and the GRS are associated with CAVD. An elevated GRS is associated with future cardiac events in a secondary risk setting, but, if the CAD status is known, it does not provide additional prognostic information.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwae100","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T20:19:36Z","timestamp":1712693976000},"page":"1303-1311","source":"Crossref","is-referenced-by-count":11,"title":["Association between lipoprotein(a), <i>LPA<\/i> genetic risk score, aortic valve disease, and subsequent major adverse cardiovascular events"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4830-7023","authenticated-orcid":false,"given":"Matthew K","family":"Moore","sequence":"first","affiliation":[{"name":"Department of Medicine, HeartOtago, Dunedin School of Medicine, University of Otago , 201 Great King Street, Dunedin 9016 , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6950-4210","authenticated-orcid":false,"given":"Gregory T","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Dunedin School of Medicine, University of Otago , 201 Great King Street, Dunedin 9016 , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9857-0703","authenticated-orcid":false,"given":"Sally","family":"McCormick","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Otago , 710 Cumberland Street, Dunedin 9016 , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4822-4962","authenticated-orcid":false,"given":"Michael J A","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Medicine, HeartOtago, Dunedin School of Medicine, University of Otago , 201 Great King Street, Dunedin 9016 , New Zealand"},{"name":"Department of Cardiology, Dunedin Hospital, Te Whatu Ora\/Health New Zealand , 201 Great King Street, Dunedin 9016 , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2312-4666","authenticated-orcid":false,"given":"Sean","family":"Coffey","sequence":"additional","affiliation":[{"name":"Department of Medicine, HeartOtago, Dunedin School of Medicine, University of Otago , 201 Great King Street, Dunedin 9016 , New Zealand"},{"name":"Department of Cardiology, Dunedin Hospital, Te Whatu Ora\/Health New Zealand , 201 Great King Street, Dunedin 9016 , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"2024080903372652700_zwae100-B1","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics\u20142021 update: a report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"2024080903372652700_zwae100-B2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0735-1097(96)00563-3","article-title":"Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study","volume":"29","author":"Stewart","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"2024080903372652700_zwae100-B3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.amjcard.2009.10.071","article-title":"Incidence and progression of aortic valve calcium in the Multi-ethnic Study of Atherosclerosis (MESA)","volume":"105","author":"Owens","year":"2010","journal-title":"Am J Cardiol"},{"key":"2024080903372652700_zwae100-B4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2174\/1570161116666180101165306","article-title":"Aortic stenosis, aortic regurgitation and arterial hypertension","volume":"17","author":"Katsi","year":"2019","journal-title":"Curr Vasc Pharmacol"},{"key":"2024080903372652700_zwae100-B5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jacc.2019.10.050","article-title":"Obesity as a causal risk factor for aortic valve stenosis","volume":"75","author":"Kaltoft","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024080903372652700_zwae100-B6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijcard.2018.03.099","article-title":"Type 1 and type 2 diabetes mellitus and incidence of seven cardiovascular diseases","volume":"262","author":"Larsson","year":"2018","journal-title":"Int J Cardiol"},{"key":"2024080903372652700_zwae100-B7","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/2047487318756131","article-title":"Association between serum calcium, serum phosphate and aortic stenosis with implications for prevention","volume":"25","author":"Wald","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"2024080903372652700_zwae100-B8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jacc.2021.11.043","article-title":"Lipoprotein(a) and body mass compound the risk of calcific aortic valve disease","volume":"79","author":"Kaltoft","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024080903372652700_zwae100-B9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.atherosclerosis.2022.02.016","article-title":"Plasma lipoprotein(a) measured in routine clinical care and the association with incident calcified aortic valve stenosis during a 14-year observational period","volume":"349","author":"Wodaje","year":"2022","journal-title":"Atherosclerosis"},{"key":"2024080903372652700_zwae100-B10","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2024080903372652700_zwae100-B11","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"2024080903372652700_zwae100-B12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors Collaboration","year":"2009","journal-title":"JAMA"},{"key":"2024080903372652700_zwae100-B13","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2024080903372652700_zwae100-B14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2024080903372652700_zwae100-B15","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/CIRCULATIONAHA.120.045826","article-title":"Lipoprotein(a) in Alzheimer, atherosclerotic, cerebrovascular, thrombotic, and valvular disease: Mendelian randomization investigation","volume":"141","author":"Larsson","year":"2020","journal-title":"Circulation"},{"key":"2024080903372652700_zwae100-B16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","article-title":"Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays","volume":"289","author":"Scharnagl","year":"2019","journal-title":"Atherosclerosis"},{"key":"2024080903372652700_zwae100-B17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10557-016-6648-3","article-title":"Human genetics and the causal role of lipoprotein(a) for various diseases","volume":"30","author":"Kronenberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"2024080903372652700_zwae100-B18","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/bjs.10224","article-title":"Comparison of three targeted approaches to screening for abdominal aortic aneurysm based on cardiovascular risk","volume":"103","author":"Jones","year":"2016","journal-title":"Br J Surg"},{"key":"2024080903372652700_zwae100-B19","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jacc.2017.12.048","article-title":"2017 cardiovascular and stroke endpoint definitions for clinical trials","volume":"71","author":"Hicks","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2024080903372652700_zwae100-B20","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/15592294.2020.1739797","article-title":"DNA methylation profiling identifies a high effect genetic variant for lipoprotein(a) levels","volume":"15","author":"Jones","year":"2020","journal-title":"Epigenetics"},{"key":"2024080903372652700_zwae100-B21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamacardio.2020.5398","article-title":"Clinical utility of lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease","volume":"6","author":"Trinder","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2024080903372652700_zwae100-B22","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2024080903372652700_zwae100-B23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2024080903372652700_zwae100-B24","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2020"},{"key":"2024080903372652700_zwae100-B25","author":"Kassambara"},{"key":"2024080903372652700_zwae100-B26","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"key":"2024080903372652700_zwae100-B27","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1136\/heartjnl-2021-319044","article-title":"Lipoprotein(a) is robustly associated with aortic valve calcium","volume":"107","author":"Kaiser","year":"2021","journal-title":"Heart"},{"key":"2024080903372652700_zwae100-B28","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/ATVBAHA.115.306683","article-title":"Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in white and black individuals: the multi-ethnic study of atherosclerosis","volume":"36","author":"Cao","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2024080903372652700_zwae100-B29","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024080903372652700_zwae100-B30","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2024080903372652700_zwae100-B31","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1161\/STROKEAHA.120.030616","article-title":"Elevated lp(a) (lipoprotein[a]) levels increase risk of 30-day major adverse cardiovascular events in patients following carotid endarterectomy","volume":"51","author":"Waissi","year":"2020","journal-title":"Stroke"},{"key":"2024080903372652700_zwae100-B32","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J Clin Lipidol"},{"key":"2024080903372652700_zwae100-B33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jacc.2021.05.037","article-title":"Frequent LPA KIV-2 variants lower lipoprotein(a) concentrations and protect against coronary artery disease","volume":"78","author":"Schachtl-Riess","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024080903372652700_zwae100-B34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/heartjnl-2014-307020","article-title":"The modern epidemiology of heart valve disease","volume":"102","author":"Coffey","year":"2016","journal-title":"Heart"},{"key":"2024080903372652700_zwae100-B35","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"AIM-HIGH Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"2024080903372652700_zwae100-B36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"HPS2-THRIVE Collaborative Group","year":"2014","journal-title":"N Engl J Med"},{"key":"2024080903372652700_zwae100-B37","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"2024080903372652700_zwae100-B38","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"key":"2024080903372652700_zwae100-B39","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/HCO.0000000000000901","article-title":"The current landscape of lipoprotein(a) in calcific aortic valvular disease","volume":"36","author":"Hsieh","year":"2021","journal-title":"Curr Opin Cardiol"},{"key":"2024080903372652700_zwae100-B40","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1161\/01.ATV.0000255952.47980.c2","article-title":"Aortic valve calcification: determinants and progression in the population","volume":"27","author":"Messika-Zeitoun","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2024080903372652700_zwae100-B41","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.jacc.2007.07.064","article-title":"Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the cardiovascular health study","volume":"50","author":"Novaro","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2024080903372652700_zwae100-B42","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/heartjnl-2012-302265","article-title":"The evolving epidemiology of valvular aortic stenosis. The Tromso study","volume":"99","author":"Eveborn","year":"2013","journal-title":"Heart"},{"key":"2024080903372652700_zwae100-B43","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/heartjnl-2016-310894","article-title":"Epidemiology of valvular heart disease in a Swedish nationwide hospital-based register study","volume":"103","author":"Andell","year":"2017","journal-title":"Heart"},{"key":"2024080903372652700_zwae100-B44","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.jacc.2017.01.025","article-title":"Association between cardiovascular risk factors and aortic stenosis: the CANHEART aortic stenosis study","volume":"69","author":"Yan","year":"2017","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwae100\/57192690\/zwae100.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/31\/10\/1303\/58778539\/zwae100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/31\/10\/1303\/58778539\/zwae100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T03:38:19Z","timestamp":1723174699000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/31\/10\/1303\/7642970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,4,9]]},"published-print":{"date-parts":[[2024,8,9]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwae100","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,4,9]]}}}